Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - 20 years patent validity
Conduit Pharmaceuticals (Nasdaq: CDT) has received approval for a composition of matter patent from IP Australia for its lead asset, an HK-4 Glucokinase Activator targeting autoimmune diseases. The company is enrolled in the Patent Prosecution Highway (PPH) program, which may fast-track patent approvals in major markets like the U.S., Europe, and Japan. The patent, valid for up to 20 years, covers cocrystals of AZD1656, identified through innovative solid-form technology.
This approval enhances Conduit's intellectual property portfolio and strengthens its position for future out-licensing opportunities. The cocrystal patents are classified as 'drug substance' patents in the FDA's Orange Book, adding significant value to the company's assets. Dr. David Tapolczay, CEO, emphasized that this approval validates their R&D capabilities and optimizes their IP portfolio's value.